Disease stage-related survival in idiopathic pulmonary fibrosis patients treated with nintedanib and pirfenidone: An exploratory study

Marialuisa Bocchino,Dario Bruzzese,Giulia Scioscia,Ludovica Capitelli,Pasquale Tondo,Gaetano Rea,Maria Pia Foschino Barbaro,Donato Lacedonia

Respiratory Medicine and Research（2023）

引用 1|浏览3

暂无评分

摘要

GAP and TORVAN similarly perform in IPF patients on anti-fibrotic therapy. However, the survival of patients treated with nintedanib and pirfenidone appears to be differently affected by disease staging.

查看译文

关键词

Nintedanib, Pirfenidone, Idiopathic pulmonary fibrosis, GAP, TORVAN

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要